Search

Displaying results 1411 - 1420 of 8170 in total
  1. Drug

    Recombinant stabilized RSV A prefusion F antigen

    go.drugbank.com/drugs/DB18713
    ApprovedInvestigational

    [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … contrast to another RSV vaccine, [respiratory syncytial virus vaccine, adjuvanted] (Arexvy), Abrysvo is reconstituted with sterile water prior to injection and does not require the co-administration of an

  2. Drug

    PF-05089771

    go.drugbank.com/drugs/DB14856
    Investigational

    PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).

  3. Drug

    PF-05180999

    go.drugbank.com/drugs/DB14885
    Investigational

    PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999).

  4. Drug

    PF-04937319

    go.drugbank.com/drugs/DB15009
    Investigational

    PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).

  5. Drug

    Sodium cellulose phosphate

    go.drugbank.com/drugs/DB06776
    Approved

    [A31694] This compound is an ion-exchange resin that can not be absorbed by the body. However, it can be used to restore normal intestinal calcium absorption.

  6. Drug

    Deferiprone

    go.drugbank.com/drugs/DB08826
    ApprovedInvestigational

    Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. … Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates
  7. Drug

    Halothane

    go.drugbank.com/drugs/DB01159
    ApprovedVet approvedWithdrawn

    A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce suffi...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 Substrates
  8. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    [L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  9. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth f...

  10. Drug

    Afatinib

    go.drugbank.com/drugs/DB08916
    ApprovedInvestigational

    use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates